Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials

Background: There is often a finite progression-free interval of time between one systemic therapy and the next when treating patients with advanced cancer. While it appears that progression-free survival (PFS) between systemic therapies tends to get shorter for a number of factors, there has not be...

Descripción completa

Detalles Bibliográficos
Autores principales: Bailey, Christopher H., Jameson, Gayle, Sima, Chao, Fleck, Sharon, White, Erica, Von Hoff, Daniel D., Weiss, Glen J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2011
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3245603/
https://www.ncbi.nlm.nih.gov/pubmed/22211140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3245603/
https://www.ncbi.nlm.nih.gov/pubmed/22211140

Ejemplares similares